Abstract:<h3 class="Heading">Background</h3><p class="Para">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are being wildly used as target therapy in non-small-cell lung cancer (NSCLC). However, NSCLC patients with wild-type EGFR and KRAS mutation are primary resistant to EGFR-TKIs such as gefitinib. Curcumin has been known as a potential therapeutic agent for several major human cancers. In this study, we investigated the effect of curcumin on the reversal of gefitinib resistance in NSCLC cells as well as their molecular bases.</p><h3 class="Heading">Methods</h3><p class="Para">H157 (wild-type EGFR and KARS mutation) and H1299 (wild-type EGFR and HRAS mutation) cells were treated with gefitinib or curcumin alone, or the two combination, and then cell viability, EGFR activity, expressions of Sp1 and Sp1-dependent proteins and receptor tyrosine kinases, markers of autophagy and apoptosis were examined by using CCK-8, colony formation, immunoblot, quantitative PCR, immunofluoscence, and flow cytometry assays. Also xenograft experiments were conduced to test the synergism of curcumin to gefitinib.</p><h3 class="Heading">Results</h3><p class="Para">Our results showed that curcumin significantly enhanced inhibitory effect of gefitinib on primary gefitinib-resistant NSCLC cell lines H157 and H1299. Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells. Meanwhile, combination treatment of curcumin and gefitinib caused dramatic autophagy induction, autophagic cell death and autophagy-mediated apoptosis, compared to curcumin or gefitinib treatment alone, as evidenced by the findings that curcumin and gefitinib combination treatment-produced synergistic growth inhibition and apoptosis activation can be reversed by pharmacological autophagy inhibitors (Baf A1 or 3-MA) or knockdown of Beclin-1 or ATG7, also can be partially returned by pan-caspase inhibitor (Z-VAD-FMK) in H157 and H1299 cells. Xenograft experiments in vivo yielded similar results.</p><h3 class="Heading">Conclusions</h3><p class="Para">These data indicate that the synergism of curcumin on gefitinib was autophagy dependent. Curcumin can be used as a sensitizer to enhance the efficacy of EGFR-TKIs and overcome the EGFR-TKI resistance in NSCLC patients with wild-type EGFR and/or KRAS mutation.</p>

Experimental Study of Curcumin on the Reversal of Gefitinib Resistance in Non-small Lung Cancer Cell Line

Imperatorin increased sensitivity of lung cancer CD133 +cell subsets to gefitinib by down-regulating c-met expression

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

MiR-128 Reverses the Gefitinib Resistance of the Lung Cancer Stem Cells by Inhibiting the C-Met/pi3k/akt Pathway.

Curcumin Lowers Erlotinib Resistance in Non-Small Cell Lung Carcinoma Cells with Mutated EGF Receptor.

Curcumin Reverses Chemoresistance of Human Gastric Cancer Cells by Downregulating the NF-κB Transcription Factor

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

Combined Treatment with Tnf-Alpha/Gefitinib Alleviates the Resistance to Gefitinib in Pc-9 Cells

Reversing paclitaxel-resistance of SKOV3-TR30 cell line by curcumin

Curcumin Suppresses PPARδ Expression and Related Genes in HT-29 Cells

Curcumin Enhances the Sensitivity of Lung Cancer Cells to Anti-tumor Agents

Progress of Chinese Medicine Monomers and Combinations in Intervening Gefitinib Resistance in Non-small Cell Lung Cancer

Decoding potential targets and pharmacologic mechanisms of curcumin in treating non-small cell lung carcinoma via bioinformatics and molecular docking

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells

Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line

Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models

Curcumin Suppresses Colon Cancer in Vitro and in Vivo